Methylation Profiling of Epstein-Barr Virus Immediate-early Gene Promoters, BZLF1 and BRLF1 in Tumors of Epithelial, NK- and B-cell Origins

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Mar 31

PMID 22458933

Citations 14

Authors

Lili Li

Xianwei Su

Gigi Ching Gee Choi

Ya Cao

Richard F Ambinder

Qian Tao

Affiliations

Soon will be listed here.

Abstract

Background: Epstein-Barr virus (EBV) establishes its latency in EBV-associated malignancies, accompanied by occasionally reactivated lytic cycle. Promoter CpG methylation of EBV genome plays an essential role in maintaining viral latency. Two immediate-early (IE) genes, BZLF1 and BRLF1, induce the switch from latent to lytic infection. Studies of methylation-dependent binding of BZLF1 and BRLF1 to EBV promoters have been well reported, but little is known about the methylation status of BZLF1 and BRLF1 promoters (Zp and Rp) in tumor samples.

Methods: We evaluated the methylation profiles of Zp and Rp by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS), as well as BZLF1 and BRLF1 expression by semiquantitative reverse transcription (RT)-PCR in tumors of epithelial, NK- and B-cell origins.

Results: We found that both Zp and Rp were hypermethylated in all studied EBV-positive cell lines and tumors of lymphoid (B- or NK cell) or epithelial origin, while unmethylated Zp and Rp alleles were detected in cell lines expressing BZLF1 and BRLF1. Following azacytidine treatment or combined with trichostatin A (TSA), the expression of BZLF1 and BRLF1 was restored along with concomitant promoter demethylation, which subsequently induced the reactivation of early lytic gene BHRF1 and late lytic gene BLLF1.

Conclusions: Hypermethylation of Zp and Rp mediates the frequent silencing of BZLF1 and BRLF1 in EBV-associated tumors, which could be reactivated by demethylation agent and ultimately initiated the EBV lytic cascade.

Citing Articles

Virological Markers in Epstein-Barr Virus-Associated Diseases.

Lupo J, Truffot A, Andreani J, Habib M, Epaulard O, Morand P Viruses. 2023; 15(3).

PMID: 36992365 PMC: 10051789. DOI: 10.3390/v15030656.

Gastric Cancer and Viruses: A Fine Line between Friend or Foe.

Firoz A, Ali H, Rehman S, Rather I Vaccines (Basel). 2022; 10(4).

PMID: 35455349 PMC: 9025827. DOI: 10.3390/vaccines10040600.

Epigenetic control of the Epstein-Barr lifecycle.

Guo R, Gewurz B Curr Opin Virol. 2021; 52:78-88.

PMID: 34891084 PMC: 9112224. DOI: 10.1016/j.coviro.2021.11.013.

Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

Heslop H, Sharma S, Rooney C J Clin Oncol. 2021; 39(5):514-524.

PMID: 33434061 PMC: 8462582. DOI: 10.1200/JCO.20.01709.

Epstein-Barr Virus Promotes B Cell Lymphomas by Manipulating the Host Epigenetic Machinery.

Di Pietro A Cancers (Basel). 2020; 12(10).

PMID: 33086505 PMC: 7603164. DOI: 10.3390/cancers12103037.

References

Cheung S, Huang D, Hui A, Lo K, Ko C, Tsang Y . Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 1999; 83(1):121-6. DOI: 10.1002/(sici)1097-0215(19990924)83:1<121::aid-ijc21>3.0.co;2-f. View

Tao Q, Swinnen L, Yang J, Srivastava G, Robertson K, Ambinder R . Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol. 1999; 155(2):619-25. PMC: 1866850. DOI: 10.1016/S0002-9440(10)65157-7. View

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

Heather J, Flower K, Isaac S, Sinclair A . The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1. J Gen Virol. 2009; 90(Pt 6):1450-1454. PMC: 2885059. DOI: 10.1099/vir.0.007922-0. View

Chen C, Li D, Guo N . Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: implications for therapy of EBV associated tumors. Cancer Biol Ther. 2009; 8(11):987-95. DOI: 10.4161/cbt.8.11.8369. View

Qiu G, Tan L, Loh K, Lim C, Srivastava G, Tsai S . The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene. 2004; 23(27):4793-806. DOI: 10.1038/sj.onc.1207632. View

Seng T, Low J, Li H, Cui Y, Goh H, Wong M . The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 2006; 26(6):934-44. DOI: 10.1038/sj.onc.1209839. View

Tao Q, Chan A . Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 2007; 9(12):1-24. DOI: 10.1017/S1462399407000312. View

Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A . Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A. 1993; 90(18):8479-83. PMC: 47380. DOI: 10.1073/pnas.90.18.8479. View

10.

Dickerson S, Xing Y, Robinson A, Seaman W, Gruffat H, Kenney S . Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters. PLoS Pathog. 2009; 5(3):e1000356. PMC: 2654727. DOI: 10.1371/journal.ppat.1000356. View

11.

Niller H, Wolf H, Minarovits J . Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol. 2009; 19(3):158-64. DOI: 10.1016/j.semcancer.2009.02.012. View

12.

Bhende P, Seaman W, Delecluse H, Kenney S . BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol. 2005; 79(12):7338-48. PMC: 1143640. DOI: 10.1128/JVI.79.12.7338-7348.2005. View

13.

Pritchett R, Hayward S, Kieff E . DNA of Epstein-Barr virus. I. Comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness. J Virol. 1975; 15(3):556-9. PMC: 354493. DOI: 10.1128/JVI.15.3.556-559.1975. View

14.

Chan A, Tao Q, Robertson K, Flinn I, Mann R, Klencke B . Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol. 2004; 22(8):1373-81. DOI: 10.1200/JCO.2004.04.185. View

15.

Wang Y, Li J, Cui Y, Li T, Ng K, Geng H . CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009; 69(12):5194-201. DOI: 10.1158/0008-5472.CAN-08-3694. View

16.

Oh S, Cha J, Shin D, Yoon S, Lee S . Establishment and characterization of an in vivo model for Epstein-Barr virus positive gastric carcinoma. J Med Virol. 2007; 79(9):1343-8. DOI: 10.1002/jmv.20876. View

17.

Ying J, Li H, Seng T, Langford C, Srivastava G, Tsao S . Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2005; 25(7):1070-80. DOI: 10.1038/sj.onc.1209154. View

18.

Niller H, Wolf H, Ay E, Minarovits J . Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease. Adv Exp Med Biol. 2011; 711:82-102. DOI: 10.1007/978-1-4419-8216-2_7. View

19.

Young L, Murray P . Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003; 22(33):5108-21. DOI: 10.1038/sj.onc.1206556. View

20.

Chang P, Chang Y, Liu S . Role of Rta in the translation of bicistronic BZLF1 of Epstein-Barr virus. J Virol. 1998; 72(6):5128-36. PMC: 110081. DOI: 10.1128/JVI.72.6.5128-5136.1998. View